V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 310005239 | 310002409 | 1.53 | 57.95 | Disease modification (D) | null | 2017-03-09 | Lenalidomide 10mg (Cycle 1 to 25) | 2 | N | 310003778 | FEC + DOCETAXEL |
| 310005240 | 310002410 | 1.72 | 125 | Palliative (P) | 2013-12-28 | 2014-01-02 | IVE | 02 | N | 310003783 | IVE |
| 310005241 | 310002411 | 1.9 | 0 | Palliative (P) | 2017-04-22 | 2017-04-22 | Cetuximab + Radiotherapy Maint | 02 | N | 310003790 | METHOTREXATE INTRATHECAL |
| 310005242 | 310002412 | 1.5 | 94.6 | Palliative (P) | 2015-06-22 | 2015-06-23 | ICON8B TRIAL | 2 | N | 310003808 | ICON8B TRIAL |
| 310005243 | 310002413 | 1.62 | null | Curative (C) | 2018-03-16 | 2018-03-18 | EC | N | N | 310003810 | EDP |
| 310005244 | 310002413 | 0 | 56 | Palliative (P) | 2016-12-05 | 2016-12-14 | CYCLOPHOSPHAMIDE + ETOPOSIDE + VINCRISTINE | 02 | N | 310003810 | BEVACIZUMAB |
| 310005245 | 310002414 | 1.64 | 57 | Palliative (P) | 2015-08-17 | 2015-08-17 | Bevacizumab + CARBOPLATIN + PACLITAXEL | N | N | 310003829 | DHAP |
| 310005246 | 310002415 | null | null | Neo-adjuvant (N) | 2019-05-20 | 2019-05-22 | Nilotinib | N | N | 310003877 | BEAM + FLUDARABINE |
| 310005247 | 310002416 | 1.65 | null | null | 2016-03-19 | 2016-03-19 | CVP R | 02 | N | 310003902 | CVP |
| 310005248 | 310002417 | 1.71 | 50 | Palliative (P) | 2018-11-19 | 2018-11-19 | ECF | 2 | N | 310004063 | IVA |
| 310005249 | 310002417 | 1.8 | 93 | Disease modification (D) | 2014-03-13 | 2014-03-25 | CAPECITABINE + CARBOPLATIN | 2 | N | 310004063 | DOCETAXEL |
| 310005250 | 310009263 | 1.57 | 84.4 | Curative (C) | 2017-09-27 | 2017-09-29 | FEC 60 or 75 | 02 | N | 310004089 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 310005251 | 310010446 | 1.8 | 0 | Curative (C) | 2016-10-06 | 2016-10-21 | Cisplatin + Fluorouracil + RT 5day | 02 | Y | 310004390 | CETUXIMAB + RT |
| 310005254 | 310009264 | 1.69 | 91.85 | Curative (C) | 2018-06-16 | 2018-06-22 | CETUXIMAB | 2 | N | 310004626 | GEFITINIB |
| 310005255 | 310002419 | 1.58 | 52.5 | Palliative (P) | 2016-12-24 | 2016-12-26 | Methotrexate High Dose (3g/m2) | N | N | 310004627 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 310005256 | 310002420 | 1.53 | null | Palliative (P) | null | 2015-09-10 | CVP R | 02 | null | 310004821 | CYCLOPHOSPHAMIDE |
| 310005257 | 310002421 | 1.6 | null | Curative (C) | 2016-08-16 | 2016-08-20 | CYCLOPHOSPHAMIDE | 01 | null | 310004863 | TRASTUZUMAB |
| 310005258 | 310002422 | 0 | 87 | Adjuvant (A) | 2017-07-23 | 2017-07-23 | Capecitabine + Cisplatin + RT | N | N | 310005127 | DABRAFENIB |
| 310005259 | 310002423 | 1.65 | null | Palliative (P) | 2015-02-13 | 2015-02-14 | Cetuximab + Radiotherapy Maint | N | N | 310005203 | ENZALUTAMIDE |
| 310005260 | 310002423 | 1.58 | 83.1 | Neo-adjuvant (N) | 2017-07-28 | 2017-08-18 | Bevacizumab 7.5mg/kg | 2 | Y | 310005203 | CAPECITABINE + CISPLATIN + RT |
| 310005261 | 310002423 | 1.73 | 71.3 | null | 2017-02-15 | 2017-02-17 | BEP 5 Day | N | N | 310005203 | ETOPOSIDE |
| 310005262 | 310002423 | 1.63 | 0 | Disease modification (D) | 2015-02-14 | 2015-02-16 | Irinotecan + Modified De Gramont | N | N | 310005203 | EC |
| 310005263 | 310002423 | 1.82 | 66.1 | Palliative (P) | 2014-08-08 | 2014-08-16 | CETUXIMAB | null | N | 310005203 | AZACITIDINE |
| 310005264 | 310002423 | 1.64 | 58.45 | null | 2014-02-21 | 2014-02-21 | IDARAM | 2 | N | 310005203 | ICON8B TRIAL |
| 310005265 | 310002423 | 1.8 | 118 | Not known (9) | 2016-11-07 | 2016-11-15 | CETUXIMAB | N | N | 310005203 | DOCETAXEL |
| 310005266 | 310002423 | 1.87 | 94 | Adjuvant (A) | 2014-07-04 | 2014-07-18 | Docetaxel 75mg/m2 (21 day) | N | N | 310005203 | DOCETAXEL |
| 310005267 | 310002423 | 0 | 94.1 | Curative (C) | 2015-08-27 | 2015-08-28 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN | 02 | N | 310005203 | NIVOLUMAB |
| 310005268 | 310002423 | 1.58 | null | Adjuvant (A) | 2014-09-14 | 2014-09-22 | Cladribine (subcut) 5 days | N | N | 310005203 | IRINOTECAN + MDG |
| 310005269 | 310002424 | 0 | 75.4 | Palliative (P) | null | 2018-05-28 | Bevacizumab 7.5mg/kg | N | N | 310005853 | ICON8B TRIAL |
| 310005270 | 310002425 | 1.61 | 53.7 | Palliative (P) | 2013-08-07 | 2013-08-10 | EVEROLIMUS | 02 | N | 310005975 | ICON8B TRIAL |
| 310005271 | 310002426 | 1.73 | 78.5 | Palliative (P) | 2017-12-23 | 2017-12-25 | POUT TRIAL | 02 | N | 310006107 | ALEMTUZUMAB |
| 310005272 | 310002427 | 1.58 | 67.7 | Adjuvant (A) | 2014-09-13 | 2014-09-13 | R GCVP | null | N | 310006136 | MELPHALAN |
| 310005273 | 310002428 | 1.89 | 62.4 | Disease modification (D) | 2016-10-20 | 2016-11-16 | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | N | Y | 310006343 | DOCETAXEL |
| 310005274 | 310002429 | 0 | 0 | Disease modification (D) | 2013-07-16 | 2013-11-10 | DABRAFENIB | null | N | 310006356 | CETUXIMAB + RT |
| 310005275 | 310002430 | 1.79 | 69.8 | Disease modification (D) | 2016-09-19 | 2016-10-03 | DABRAFENIB | N | N | 310006372 | DA |
| 310005276 | 310007004 | 0 | 74.7 | Curative (C) | 2015-09-08 | 2015-09-08 | CVP | N | N | 310006378 | BEP |
| 310005277 | 310007004 | null | 56.7 | Not known (9) | 2017-02-03 | 2017-03-03 | Sunitinib | N | N | 310006378 | VINCRISTINE |
| 310005278 | 310007004 | 1.87 | null | null | 2016-10-26 | 2016-10-30 | Trabectedin | 02 | Y | 310006378 | DOCETAXEL + FLUOROURACIL + OXALIPLATIN |
| 310005279 | 310011101 | 1.9 | null | Curative (C) | null | 2013-08-22 | CYCLOPHOSPHAMIDE | N | null | 310006548 | CARBOPLATIN + RT |
| 310005280 | 310011101 | null | 92 | Not known (9) | 2015-02-14 | 2016-08-14 | Cisplatin + Fluorouracil + RT 5day | N | N | 310006548 | MITOMYCIN |
| 310005281 | 310011101 | 1.75 | 118 | Palliative (P) | 2015-10-29 | 2015-11-02 | MVAC | N | N | 310006548 | METHOTREXATE HIGH DOSE |
| 310005282 | 310011805 | 1.55 | 0 | Palliative (P) | 2013-11-16 | 2013-11-17 | ICON8B TRIAL | 02 | N | 310006677 | BEVACIZUMAB + CARBO + GEMCITABINE |
| 310005283 | 310011805 | 0 | 0 | Curative (C) | 2013-05-22 | 2013-06-06 | ICON8B TRIAL | N | N | 310006677 | CISPLATIN + VINORELBINE |
| 310005284 | 310011805 | 1.6 | 49.2 | Palliative (P) | 2016-07-15 | 2016-07-16 | METHOTREXATE | Y | Y | 310006677 | IFOSFAMIDE |
| 310005285 | 310011805 | 1.58 | null | Disease modification (D) | 2018-01-20 | 2018-02-03 | METHOTREXATE | null | N | 310006677 | MITOMYCIN |
| 310005286 | 310011805 | 1.6 | 55.7 | Adjuvant (A) | 2016-08-10 | 2016-08-14 | DHAP | 2 | null | 310006677 | TRASTUZUMAB |
| 310005287 | 310002431 | 1.77 | 76.2 | Palliative (P) | 2013-05-09 | 2013-05-10 | BEP 5 Day | 2 | N | 310007004 | GDP R |
| 310005288 | 310007005 | 1.56 | 80.3 | Disease modification (D) | 2017-05-23 | 2017-06-02 | Epirubicin (weekly) | N | N | 310007069 | EVEROLIMUS |
| 310005289 | 310002432 | 1.77 | null | Curative (C) | 2017-08-10 | 2017-08-25 | DABRAFENIB | 02 | N | 310007268 | CYCLO + ETOPOSIDE + VINCRISTINE |
| 310005290 | 310002433 | 1.73 | null | Palliative (P) | 2014-12-26 | 2014-12-28 | Doxorubicin + Ifosfamide | 02 | N | 310007286 | ABIRATERONE |